BlackRock Updates Passive Stake in Atea Pharmaceuticals
Ticker: AVIR · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock just updated its passive stake in Atea Pharma as of year-end 2023.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating its ownership in Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) as of December 31, 2023. This filing, Amendment No. 3, shows BlackRock's updated passive investment position in Atea's Common Stock. For investors, this matters because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or investment strategy for Atea Pharmaceuticals.
Why It Matters
This filing shows BlackRock's updated ownership in Atea Pharmaceuticals, providing transparency on a major institutional investor's position, which can influence market perception.
Risk Assessment
Risk Level: low — This is a routine update from a passive investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
A smart investor would note BlackRock's continued passive stake as a sign of long-term institutional presence but would not make immediate trading decisions based solely on this routine amendment. Further research into Atea's fundamentals and BlackRock's overall portfolio strategy would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person filing the SC 13G/A
- Atea Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- 04683R106 (string) — the CUSIP number for Atea Pharmaceuticals' Common Stock
Forward-Looking Statements
- BlackRock will maintain a passive investment strategy in Atea Pharmaceuticals for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
- Atea Pharmaceuticals' stock price will not experience significant volatility directly due to this routine filing. (Atea Pharmaceuticals, Inc.) — high confidence, target: February 24, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating a change in beneficial ownership by a passive investor.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a large asset management firm.
What is the subject company whose shares are being reported?
The subject company is Atea Pharmaceuticals, Inc., identified by CIK 0001593899 and SIC 2834 (Pharmaceutical Preparations).
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event requiring this filing was December 31, 2023.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Atea Pharmaceuticals, Inc. is 04683R106.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Atea Pharmaceuticals, Inc. (AVIR).